Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author does not hold a position in RXRX.
← Back to Free Index

RXRX

Analysis as of: 2026-02-20
Recursion Pharmaceuticals, Inc.
Recursion is a clinical-stage TechBio company combining automated wet-lab experimentation and machine learning to discover and develop drugs and run biopharma collaborations.
ai automation biotech healthcare
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Platform-to-product re-rate hinges on 2026 proof points
The setup is a cash-backed TechBio platform with a lead program showing early clinical signal and a dense 2026–2027 catalyst path. Upside comes from converting proof points into registrational momentum and partner economics that look like validated outcomes, not services.

Analysis

Thesis
RXRX’s non-linear upside is a re-rating from “AI discovery story” to “evidence-to-asset factory”: if REC-4881 converts into an FDA-aligned registrational path and partner deals shift toward standardized, outcome-priced deliverables with auditable provenance, revenue can inflect while dilution risk falls, enabling a multi-asset biotech valuation by 2031.
Last Economy Alignment
They own a rare combination of proprietary biological/chemical data, automated lab throughput, and dedicated compute—control points that compound as models get cheaper. The key obsolescence risk is that pharma in-sources AI discovery and pushes platform economics back toward commodity services unless Recursion proves repeatable clinical translation.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
5.8x (from 5 most recent analyses)
Reasoning
RXRX can grow into a hybrid model by 2031: (1) one internal program reaching commercialization or late-stage economics, (2) milestone/royalty-bearing collaborations that increasingly pay for validated endpoints (not effort), and (3) platform upgrades that raise switching costs via provenance and reproducibility. The stock is priced like “optional R&D spend,” so repeatable human proof points can drive a step-change re-rate even before peak sales.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The dominant risk is clinical/regulatory proof: without repeatable human efficacy and an FDA-credible registrational plan, the platform won’t earn durable economics. Second-order risks are dilution (if burn stays high), partner in-sourcing/commoditization pressuring collaboration value capture, and fixed-cost fragility from maintaining compute + wet-lab throughput through cycles.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.44
They control a compounding loop of proprietary data, automated experiments, and compute that can turn cheaper AI into faster drug decisions. The threat is that big pharma builds similar stacks in-house, so durable value requires repeatable clinical wins and trusted, auditable deliverables.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$7.00
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case